Evolent Health, INC

Evolent Health announced its first quarter 2026 financial results, reporting increased revenue and a reduced net loss, while reaffirming its full-year guidance.

Evolent Health announced its fourth quarter and full year 2025 financial results, reporting a significant net loss driven by goodwill impairment, despite growth in adjusted EBITDA and a strong 2026 revenue outlook.

Evolent Health, Inc. announced the completion of its previously disclosed stock purchase agreement with Privia Management Company, LLC.

Evolent Health announces a new independent director appointment to its Board and reaffirms its fourth quarter 2025 revenue and Adjusted EBITDA guidance.

Evolent Health reported strong third-quarter 2025 financial results, exceeding expectations, and announced significant leadership team restructuring to support accelerating growth.

Evolent Health announced the strategic divestiture of its Evolent Care Partners business for up to $113 million, reaffirming its Q3 and full-year 2025 financial guidance.

Evolent Health reported a 2.6% revenue increase in Q1 2026, driven by new contracts, but saw its net loss widen due to higher claims costs and increased interest expenses.

Evolent Health reported a 22.8% revenue decline in Q3 2025 due to contractual changes, but improved operating income, while undertaking significant debt refinancing and asset disposal.

Evolent Health, Inc. reported a significant revenue decrease and increased net loss for Q2 2025, driven by customer contract changes and higher medical claims costs, while actively restructuring its debt.

Evolent Health's Q1 2025 revenue decreased by 24.4% year-over-year, primarily due to contractual updates and industry-wide medical claims cost increases.

Evolent Health's Q3 2024 revenue increased by 21.6% year-over-year, but higher-than-expected medical costs in its specialty Performance Suite business impacted profitability.

Evolent Health's Q2 2024 results show a significant revenue increase driven by new risk contracts, while the company concludes its 2023 repositioning plan.

Evolent Health reported a substantial net loss of $579.4 million and a 26.6% revenue decrease in 2025, driven by contractual changes and a $398.0 million goodwill impairment.

Evolent Health's 2024 10-K filing highlights strategic shifts towards value-based specialty care, acquisitions, and financial challenges due to rising medical costs.

Evolent Health's 2023 annual report details its financial performance, strategic acquisitions, and focus on value-based specialty care.

Evolent Health CEO Seth Blackley reported transactions involving restricted stock units and common stock, including a significant grant of RSUs.

Evolent Health's General Counsel, Jonathan Weinberg, reported transactions involving restricted stock units and common stock, including shares withheld for tax obligations.

Evolent Health's President, Daniel Joseph McCarthy, reported transactions involving Class A Common Stock, including the acquisition of restricted stock units and the withholding of shares for tax obligations.

Evolent Health, Inc. reports that Chief Accounting Officer Shams Aammaad was granted 28,790 restricted stock units under the company's 2015 Omnibus Incentive Compensation Plan.

Evolent Health Director Toyin Ajayi acquired 41,096 shares of Class A Common Stock through restricted stock units.

Evolent Health Director Russell Monroe Glass acquired 41,096 shares of Class A Common Stock through a restricted stock unit grant.

Evolent Health's 2026 proxy statement outlines executive compensation adjustments, board refreshment, and a proposal to increase shares under its incentive plan following a challenging 2025.

Evolent Health's 2025 Annual Meeting will address director elections, auditor ratification, executive compensation, and an amendment to the incentive compensation plan.

Evolent Health's 2025 proxy statement highlights board changes, executive compensation, and a proposal to amend the 2015 Omnibus Incentive Compensation Plan to support future growth.

Evolent Health, Inc. has scheduled its 2024 Annual Meeting for June 6, 2024, and is urging shareholders to vote on key proposals, including the election of directors, ratification of the independent auditor, and executive compensation.

Evolent Health's 2024 proxy statement outlines key proposals for the annual stockholder meeting, including director elections, auditor ratification, and advisory votes on executive compensation.

The Vanguard Group filed an amended Schedule 13G, reporting zero beneficial ownership in Evolent Health Inc. following an internal reporting realignment.

Eventide Asset Management, Finny Kuruvilla, and Robin C. John have filed an amended Schedule 13G, disclosing a 0.0% beneficial ownership in Evolent Health, Inc. Class A Common Stock as of December 31, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, reported beneficial ownership of 8.1% of Evolent Health, Inc.'s Class A Common Stock as of December 31, 2025.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a beneficial ownership of 0.7% of Evolent Health Inc.'s Class A Common Stock as of December 31, 2025.

The Vanguard Group reported a 7.98% beneficial ownership stake in Evolent Health Inc., holding 8,914,065 common shares as of December 31, 2025.

Rubicon Fund II LP and affiliated entities, including Adam Boehler, have disclosed a 5.21% beneficial ownership stake in Evolent Health, Inc.'s Class A Common Stock.